Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting

Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting

Background: In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy. Objectives: The aim of this retrospective multicenter real-world cohort study was t...

Full description

Bibliographic Details
Main Authors: Manon Falette-Puisieux, Jean-Charles Nault, Mohamed Bouattour, Marie Lequoy, Giuliana Amaddeo, Thomas Decaens, Frederic Di Fiore, Sylvain Manfredi, Philippe Merle, Aurore Baron, Christophe Locher, Anna Pellat, Romain Coriat
Format: Article
Language:English
Published: SAGE Publishing 2023-08-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359231189425

Internet

https://doi.org/10.1177/17588359231189425

Similar Items